Tag:
Impax Pharmaceuticals
Latest Headlines
Latest Headlines
Impax licenses U.S. rights to AstraZeneca migraine drug, variations likely
Impax Pharmaceuticals is paying AstraZeneca ( $AZN ) $130 million so it can license U.S. commercial rights for three versions of the migraine drug Zomig. Their agreement also allows for new variations
